Rasburicase for the treatment of tumor lysis in hematological malignancies (Q37978342)

26 August 2017

title

Rasburicase for the treatment of tumor lysis in hematological malignancies (English)

1 reference

26 August 2017

Giulia Malaguarnera

1

1 reference

26 August 2017

Maria Giordano

series ordinal

2

1 reference

26 August 2017

Mariano Malaguarnera

series ordinal

3

1 reference

26 August 2017

publication date

1 February 2012

1 reference

Expert Review of Hematology

26 August 2017

published in

1 reference

26 August 2017

volume

5

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

27-38

1 reference

Tumour lysis syndrome: new therapeutic strategies and classification

26 August 2017

cites work

1 reference

Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus

21 January 2018

1 reference

The clinical management of tumour lysis syndrome in haematological malignancies

21 January 2018

1 reference

Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

21 January 2018

1 reference

21 January 2018

1 reference

Acute renal failure: a practical update

21 January 2018

1 reference

Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase

21 January 2018

1 reference

Renal failure associated with cancer and its treatment: an update

21 January 2018

1 reference

Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review

21 January 2018

1 reference

A review of clinical and laboratory findings and treatment of tumor lysis syndrome

21 January 2018

1 reference

Fatal acute tumor lysis syndrome following intrathecal chemotherapy for acute lymphoblastic leukemia with meningeal involvement.

21 January 2018

1 reference

Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

21 January 2018

1 reference

Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome

21 January 2018

1 reference

Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature

21 January 2018

1 reference

Fatal acute tumor lysis syndrome with metastatic breast carcinoma.

21 January 2018

1 reference

Acute tumor lysis syndrome with metastatic medulloblastoma: A case report

21 January 2018

1 reference

The management of tumor lysis syndrome.

21 January 2018

1 reference

Management of tumor lysis syndrome in adults

21 January 2018

1 reference

Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration

21 January 2018

1 reference

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.

21 January 2018

1 reference

Protective effect of urate oxidase on uric acid induced-monocyte apoptosis

21 January 2018

1 reference

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

21 January 2018

1 reference

Urate oxidase: primary structure and evolutionary implications

21 January 2018

1 reference

Soybean Nodule-Specific Uricase (Nodulin-35) Is Expressed and Assembled into a Functional Tetrameric Holoenzyme in Escherichia coli

21 January 2018

1 reference

Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations

21 January 2018

1 reference

The role of uric acid in protection against peroxynitrite-mediated pathology

21 January 2018

1 reference

Cloning, purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli.

21 January 2018

1 reference

Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia

21 January 2018

1 reference

Modification of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase

21 January 2018

1 reference

Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase

21 January 2018

1 reference

A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy

21 January 2018

1 reference

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy

21 January 2018

1 reference

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.

21 January 2018

1 reference

Advances in the management of malignancy-associated hyperuricaemia

21 January 2018

1 reference

Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study

21 January 2018

1 reference

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study

21 January 2018

1 reference

Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma

21 January 2018

1 reference

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial

21 January 2018

1 reference

Hemolysis and methemoglobinemia secondary to rasburicase administration

21 January 2018

1 reference

Rasburicase: a potent uricolytic agent

21 January 2018

1 reference

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

21 January 2018

1 reference

Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout

21 January 2018

1 reference

A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure.

21 January 2018

1 reference

Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis

21 January 2018

1 reference

Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience

21 January 2018

1 reference

Elevated uric acid increases the risk for kidney disease

21 January 2018

1 reference

Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2.

21 January 2018

1 reference

Gout: on the brink of novel therapeutic options for an ancient disease

21 January 2018

1 reference

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

21 January 2018

1 reference

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 January 2018

1 reference

Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol

21 January 2018

1 reference

Tumor lysis syndrome: pathogenesis and management

21 January 2018

1 reference

Consensus conference on the management of tumor lysis syndrome

21 January 2018

1 reference

A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome

21 January 2018

1 reference

Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.

21 January 2018

1 reference

Rasburicase for the treatment and prevention of hyperuricemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.11.73

1 reference

26 August 2017

1 reference